Wheeler v. Novartis Pharmaceuticals Corp.

ORDER

J. RANDAL HALL, District Judge.

Presently pending before the Court is Defendant’s motion for summary judgment. (Doc. no. 28.) For the following reasons, this motion is GRANTED.

I. BACKGROUND

A. Zometa and Osteonecrosis of the Jaw

Zometa is a bisphosphonate medication prescribed to patients with hypercalcemia of malignancy, multiple myeloma, or certain kinds of cancer that have metastasized to the bones. (Doc. no. 28, Ex. 5.) Zometa may reduce skeletal events that can result from these advanced cancers. (Id.) In 2002, the United States Food and Drug Administration (“FDA”) approved Zometa as a…